

DayTwo's glycemic control solution uses gut profiling and other clinical parameters to provide a food-as-medicine solution to enable glycemic control. It's personalized approach provides actionable insights into how the body metabolizes food and allows individuals to navigate what specific foods and meals to choose to balance their blood sugar levels.

Yahal Zilka, Managing Partner at Ofek Ventures said, "We are undergoing a transformational change in healthcare, when technology and machine learning can benefit patients with diabetes."

"After success in its initial market, we are excited to bring DayTwo to the U.S. where it has the potential to improve the lives of over one hundred million people with diabetes and prediabetes," added Zilka, whose investment track record includes Waze, Argus, Onavo, DesignArt, Magisto (acquired by Google), Continental, Facebook, Qualcomm, and Vimeo, respectively.

Yair Schindel Managing Partner aMoon Fund said, "Digital health solutions such as DayTwo's accelerate treatment, disease prevention, and management of chronic illnesses. As a doctor who has witnessed first-hand the harmful effects of metabolic diseases, I am encouraged by the positive results among the tens of thousands of patients served by DayTwo. The company's ability to make precision medicine accessible through their glycemic-control solution is helping people with diabetes today; I feel fortunate to witness this as the company expands to the United States."

DayTwo's food-as-medicine approach is based on the original research conducted by Professors Eran Segal and Eran Elinav at The Weizmann Institute of Science, published in the journal, Cell, in 2015. The Cell paper demonstrated how the gut microbiome, in conjunction with other clinical and personal parameters, can enable personalized dietary interventions that can successfully balance post-meal glucose response.

Irit Poraz, Head Dietitian, at Clalit said, "We partnered with DayTwo to realize the full potential of personalization in both preventative care and chronic condition management. The era of food-as-medicine is here. DayTwo is a pioneer that has brought the only evidence-based, actionable microbiome derived solution to the market. We are pleased to be able to leverage this science and actionability for our plan members."

DayTwo continues to conduct ongoing research with clinical institutional partners including the Weizmann Institute of Science, the Israel Diabetes Association, Joslin Diabetes Center, Janssen a Pharmaceutical Company of Johnson & Johnson, and the Mayo Clinic.